key: cord-1025327-wi2qpl54 authors: Truong, Thao T.; Bard, Jennifer Dien; Butler-Wu, Susan M. title: Rapid antigen assays for SARS-CoV-2: Promise and peril date: 2022-03-04 journal: Clin Lab Med DOI: 10.1016/j.cll.2022.03.001 sha: d14233e8ca62c3af808b6bdc64bd25de9743bbf0 doc_id: 1025327 cord_uid: wi2qpl54 nan show solid performance characteristics, meta-analyses show a wide range of 144 sensitivities among symptomatic patients (68.9% average sensitivity, 95% CI: 61.8 - 145 75.1%). 42 Antigen testing specificity is generally high (99.6%, 95% CI: 99.0 -99.8%), 146 though clusters of false-positive results have been described. 43 A summary of test 147 performance among common brands is shown in (Table 1) . 148 Interpretation of studies regarding the performance of antigen testing among 149 symptomatic patients can be challenging, even for assays considered to be among the 150 most sensitive on the market. For example, among symptomatic participants at a 151 community testing site in Wisconsin, the sensitivity of the Abbott BinaxNOW Ag Card 152 (BinaxNOW) lateral flow immunoassay was 78.6% (95% CI: 73.4 -83.3%) compared to 153 RT-PCR 44 162 an 82% positive agreement with RT-PCR among symptomatic patients at an urgent 163 care center. 28 The FIA also had comparable performance to the BD Veritor (Veritor) 164 chromatographic digital immunoassay antigen test in specimens collected from drive-165 through and outpatient sites, despite apparent differences in sensitivity according to 166 their respective EUA submission data. 49 167 It is generally accepted that RADTs are unlikely to be positive beyond 7 days of 168 symptoms, though this can differ somewhat by RADT brand (i.e. 5 days vs. 7 days). For 169 example, the Innova assay remained positive for several days longer than the 170 SureScreen F assay in one study. 31 J o u r n a l P r e -p r o o f divergent results may reflect differences in performance in adults versus children, 181 regional differences in patient population, or differences in PCR methodology. 182 Symptomatic testing is arguably the most high-stakes application for RADTs. 183 Antigen testing has limited utility in the diagnosis of symptomatic COVID-19 in hospital 184 settings because patients who require hospitalization can present for evaluation after 185 more than one week of symptoms. For this reason, they have been deemed to be 186 unsuitable for rapid "rule-out" in an emergency department setting. 32 Performance as a test of infectiousness in asymptomatic populations 200 The ability of antigen testing to identify infectious asymptomatic or pre-symptomatic Secondly, individuals with low viral loads, defined in one study as 1x10 6 copies/mL, had 229 a secondary attack rate that was half that of individuals with high viral loads, but was 230 still significant at 12%. 59 When the rate of local spread is high, the detection rate of 231 RADTs for specimens with lower viral loads could potentially miss a sizable portion of 232 pre-symptomatic and asymptomatic cases. 60 233 Importantly, while the limit of detection (LoD) of the BinaxNOW COVID-19 234 Antigen Card (Abbott, Scarborough, Maine) was shown to be approximately 4.0 × 10 4 to 235 8.1 × 10 4 copies per swab 30 , the LoD for several other RADT brands were shown to be 236 much higher, at 2.1 x 10 6 to 2.9 x 10 7 per swab). 61 (e.g. specimen quality, timing of testing) are similarly a consideration in this setting. 264 An additional concern is that even a test with excellent specificity will have a poor 265 positive predictive value (PPV) during periods of low infection prevalence. 69,70 For 266 example, PPV is predicted to be only 28.8% for a test with 98% specificity when disease 267 prevalence is 1% 71 . This was also shown in a real world study where a 66.7% false- -2 in a hospital setting Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for 658 Strand-specific reverse transcription PCR for detection 662 of replicating SARS-CoV-2. Emerging Infectious Diseases Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain 665 Methods to be a Surrogate for Replication-Competent Virus Accuracy of novel antigen rapid 668 diagnostics for SARS-CoV-2: A living systematic review and meta-analysis Ct Values Do Not Predict Severe Acute Respiratory 671 Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students Transmission of COVID-19 in 282 clusters in 674 Spain: a cohort study Rapid antigen detection alone may not be 677 sufficient for early diagnosis and/or mass screening of COVID-19 Comparison of seven commercial SARS-CoV-2 680 rapid point-of-care antigen tests: a single-centre laboratory evaluation study Test sensitivity is secondary to frequency and 686 turnaround time for COVID-19 screening Performance Over the Course of Acute SARS-CoV-2 Infection Surveillance testing for SARS-COV-2 695 infection in an asymptomatic athlete population: a prospective cohort study with 123 362 696 tests and 23 463 paired RT-PCR/antigen samples Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a 700 modelling analysis Rapid antigen screening of asymptomatic people as a 702 public health tool to combat COVID-19 Rapid antigen testing in COVID-19 responses Potential for False Positive Results with Antigen Tests for Rapid 707 Detection of SARS-CoV-2 -Letter to Clinical Laboratory Staff and Health Care Providers Can We Test Our Way Out of the COVID-19 Pandemic? Discontinue the Use of Antigen Testing in 714 Skilled Nursing Facilities Until Further Notice Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing 719 to Decrease SARS-CoV-2 Transmission The impact of repeated mass antigen testing for 725 COVID-19 on the prevalence of the disease On Pilot Massive COVID-19 Testing by Antigen Tests in Europe. Case 728 Study: Slovakia The impact of population-wide rapid antigen 730 testing on SARS-CoV-2 prevalence in Slovakia Severe Acute Respiratory Syndrome Coronavirus Transmission in Intercollegiate Athletics Not Fully Mitigated With Daily Antigen Testing Same-day SARS-CoV-2 antigen test screening in an 736 indoor mass-gathering live music event: a randomised controlled trial Screening for SARS-CoV-2 Antigen Before a 739 Live Indoor Music Concert: An Observational Study SARS-CoV-2 Testing Prior to International 742 Airline Travel Daily testing for contacts of individuals with 745 SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English 746 secondary schools and colleges: an open-label, cluster-randomised trial. The Lancet Performance and Implementation Evaluation of the 749 Testing Site in Massachusetts Head-to-head performance comparison of self-753 collected nasal versus professional-collected nasopharyngeal swab for a SARS-CoV-2 antigen-detecting rapid diagnostic test Comparison of Unsupervised Home Self-757 collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection Impaired performance of SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-765 administration Analytic Sensitivity of the Abbott BinaxNOW Lateral Flow Immunochromatographic Assay for the SARS-CoV-2 Omicron Variant Assessment of the analytical sensitivity of ten lateral flow 770 devices against the SARS-CoV-2 omicron variant A SARS-CoV-2 Nucleocapsid Variant that 773 Affects Antigen Test Performance Estimating infectiousness throughout SARS-CoV-776 2 infection course CoV-2 variant -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology